New Medications

CagriSema: Novo Nordisk's Next-Generation Weight Loss Drug Explained

GLP-1 Companion · 7 min read

CagriSema is a once-weekly injectable combination drug under development by Novo Nordisk. It pairs two distinct mechanisms in a single fixed-ratio injection: cagrilintide, a long-acting amylin analog, and semaglutide, the active ingredient in Ozempic and Wegovy. The goal is to target obesity from two biological angles simultaneously — GLP-1 receptor activation and amylin signaling — to achieve deeper, more durable weight loss than either drug alone. Phase 3 clinical data from the REDEFINE trials has generated significant attention, with results showing weight loss well beyond what semaglutide monotherapy has produced.

What Is CagriSema? Understanding the Mechanism

To understand why CagriSema is exciting, it helps to know what each component does separately. Semaglutide is a GLP-1 receptor agonist — it mimics the hormone GLP-1, slows gastric emptying, reduces appetite, and lowers blood sugar. You already know its effects from Ozempic and Wegovy. Cagrilintide works differently: it's a long-acting analog of amylin, a hormone naturally secreted alongside insulin from the pancreas. Amylin works in the brain to reduce appetite and slow the rate at which the stomach empties. It also suppresses glucagon, the hormone that raises blood sugar.

When you combine these two mechanisms, you are simultaneously hitting GLP-1 receptors (which regulate hunger, blood sugar, and gastric emptying) and amylin receptors (which regulate satiety signals in the brain's hypothalamus and slow gastric emptying through a separate pathway). The result, based on trial data, appears to be additive: more weight loss with a different — and sometimes more tolerable — side effect profile than dramatically higher doses of semaglutide alone.

REDEFINE Trials: What the Data Shows

The REDEFINE program is Novo Nordisk's Phase 3 clinical trial series for CagriSema. In REDEFINE 1, the large cardiovascular outcomes and obesity trial, participants treated with CagriSema 2.4 mg/2.4 mg weekly achieved approximately 22.7% average weight loss from baseline over 68 weeks — compared to around 16.1% for semaglutide 2.4 mg (Wegovy-dose) and around 10.8% for cagrilintide 2.4 mg alone. That extra 6–7 percentage points over semaglutide alone is clinically significant: for a person weighing 250 lb (113 kg), the difference between losing 40 lb and 57 lb matters enormously.

• CagriSema 2.4 mg / 2.4 mg: ~22.7% average weight loss at 68 weeks (REDEFINE 1 interim/headline data)
• Semaglutide 2.4 mg monotherapy (Wegovy): ~16.1% average weight loss
• Cagrilintide 2.4 mg monotherapy: ~10.8% average weight loss
• Placebo: ~2.3% average weight loss

Importantly, REDEFINE 2, which enrolled participants with type 2 diabetes, showed even more dramatic separation from semaglutide alone in the diabetic population. CagriSema also demonstrated improvements in blood pressure, waist circumference, and cardiometabolic markers beyond what weight change alone would predict.

CagriSema vs. Semaglutide: Is It Worth the Upgrade?

The core question for people currently on semaglutide is whether CagriSema would meaningfully change their results — and whether the trade-offs in side effects or cost make it worthwhile. Based on trial data, CagriSema appears to offer roughly 6–7 percentage points more weight loss than Wegovy-dose semaglutide. For someone who has reached a plateau on Wegovy or Ozempic, or who needs to lose a greater amount of weight, that gap is real.

However, CagriSema also showed higher rates of injection-site reactions than semaglutide alone in some sub-studies — a known nuisance with amylin analogs. GI side effects (nausea, vomiting, constipation) were in a similar range to Wegovy. The two-drug combination also requires careful dose titration, as both components are escalated over time.

CagriSema vs. Tirzepatide (Mounjaro / Zepbound)

The most common comparison people make is CagriSema vs. tirzepatide (Mounjaro/Zepbound). Tirzepatide is already FDA-approved and has shown up to 22.5% average weight loss in the SURMOUNT-1 trial at maximum dose. CagriSema's ~22.7% figure from REDEFINE 1 puts it in a similar ballpark, though direct head-to-head trial data between the two drugs does not yet exist in a large published study.

• Tirzepatide 15 mg (Zepbound): ~22.5% average body weight reduction (SURMOUNT-1) — already FDA-approved
• CagriSema 2.4/2.4 mg: ~22.7% average body weight reduction (REDEFINE 1) — still in trials as of 2026
• Mechanism differs: tirzepatide is a dual GIP/GLP-1 agonist; CagriSema is a GLP-1/amylin combination

Mechanistically, tirzepatide and CagriSema are very different drugs. Tirzepatide activates both GLP-1 and GIP receptors. CagriSema activates GLP-1 receptors and amylin receptors. The practical difference for patients may come down to tolerability, injection-site experience, and individual response — both seem to occupy the same weight-loss tier above standard semaglutide.

When Might CagriSema Be Available?

As of late 2026, CagriSema is still completing Phase 3 REDEFINE trials. Novo Nordisk has signaled plans to submit for regulatory review once full trial data is compiled. If approved on a timeline similar to other GLP-1 drugs in the approval pipeline, CagriSema could potentially be available in the US in 2027 or 2028 — though regulatory timelines are unpredictable.

Cost and insurance coverage are unknowns. Given that Wegovy already faces access challenges in the US due to price and coverage gaps, CagriSema's market penetration will depend heavily on how Novo Nordisk prices it and how quickly payers adapt their formularies.

Who Might Be a Candidate for CagriSema?

Based on trial enrollment criteria, CagriSema candidates in the trial were adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. This is broadly similar to Wegovy's labeling. The most likely first candidates, if and when it is approved, would include people who need greater weight loss than semaglutide alone can provide, people who have reached a plateau on current GLP-1 therapy, and those with type 2 diabetes who also need significant weight reduction.

The Bottom Line on CagriSema

CagriSema represents the next wave of obesity pharmacotherapy: smarter combinations that hit weight-regulating biology from multiple directions simultaneously. The trial data is genuinely impressive — pushing past 22% average weight loss is a meaningful advance over what the first generation of GLP-1 monotherapy achieves. Whether that translates into real-world approval, access, and outcomes that hold up at scale remains to be seen. For now, it's a drug to watch closely, not one you can yet ask your doctor to prescribe.

Sources

• REDEFINE 1 trial results — Novo Nordisk press releases and NEJM publications
• Cagrilintide mechanism — amylin receptor biology